ANG-1 Recombinant Protein Cat. No.: 40-229

Availability: In stock

$0.00

No Image

 Price Options

$0.00
psi-iconSpecifications
SPECIES:Human
SOURCE SPECIES:HeLa cells
TESTED APPLICATIONS:
BIOLOGICAL ACTIVITY: Determined by its ability to induce adhesion of human umbilical vein endothelial cells (HUVEC).
psi-iconProperties
PURITY:Greater than 95% by SDS-PAGE gel and HPLC analyses.

Endotoxin level is less than 0.1 ng per μg (1EU/μg).
PHYSICAL STATE:Lyophilized
STORAGE CONDITIONS:The lyophilized ANG-1 recombinant protein is stable for at least 2 years from date of receipt at -20˚C. Reconstituted ANG-1 is stable for at least 3 months when stored in working aliquots with a carrier protein at -20˚C. As with any protein, exposing ANG-1 recombinant protein to repeated freeze / thaw cycles is not recommended. When working with proteins care should be taken to keep recombinant protein at a cool and stable temperature.
psi-iconAdditional Info
ALTERNATE NAMES:AGP1, AGPT, ANG1, KIAA0003, Angiopoietin-1, ANG-1
ACCESSION NO.:NP_001137.2
PROTEIN GI NO.:20532340
OFFICIAL SYMBOL:ANGPT1
GENE ID:284
psi-iconBackground and References
BACKGROUND:Angiopoietin-1 (Ang-1) is a secreted ligand for Tie-2, a tyrosine-kinase receptor expressed primarily on vascular endothelial cells and early hematopoietic cells. Ang-1/ Tie-2 signaling promotes angiogenesis during the development, remodeling, and repair of the vascular system. Transgenic mice lacking expression of either Ang-1 or Tie-2 fail to develop a fully functional cardiovascular system and die before birth. Postnatally, the angiogenic activity of Ang-1/Tie-2 is required during normal tissue repair and remodeling of the female endometrium in the menstrual cycle. Ang-1/Tie-2 signaling appears to be regulated by Angiopoietin-2 (Ang-2), a natural antagonist for Tie-2 that exerts its effects through an internal autocrine loop mechanism. In addition to suppressing endothelial cell activation by inhibiting the expression of adhesion and inflammatory molecules, Ang-1 enhances endothelial cell survival and capillary morphogenesis, and lessens capillary permeability. As such, Ang-1 has a potential to become an effective therapeutic agent for treating various endothelium disorders, including several severe human pulmonary diseases. The efficacy of cell-based Ang-1 gene therapy for acute lung injury (ALI) has recently been studied in a rat model of ALI (1). The results of this study show that such therapy can markedly improve lung condition and suggest that Ang-1 therapy may represent a potential new strategy for the treatment and/or prevention of acute respiratory distress injury (ARDI), a significant cause of morbidity and mortality in critically ill patients. Recombinant human ANG-1, derived from HeLa cells, is a C-terminal histidine tagged glycoprotein which migrates with an apparent molecular mass of 60.0 - 70.0 kDa by SDS-PAGE under reducing conditions. Sequencing analysis shows N-terminal sequences starting with Ser-20 and with Asp-70 of the 498 amino acid precursor protein.

FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.